XCOVERY LLC
PALM BEACH GARDENS, FLORIDA

People enter clinical studies for different reasons. For example, some people have a disease where there is currently no treatment available or the available treatments didn’t show the desired effect. Joining a study of an investigational drug might give them a renewed interest. Other people might enroll in a study because their current therapy is not effective or tolerable enough and a study would provide another treatment option. The goal is that the investigated medicine has fewer side effects, is more effective or may offer other benefits. And finally, some people might volunteer because they wish to help improve medicines that will help others in the future. The purpose of a clinical study is to learn more about a medicine’s ability to work safely and effectively. Therefore there may be risks related to these drugs that will only become apparent in the course of the study. Your doctor will discuss all potential risks with you and will help you to weigh them against the possible benefits. It is important that you ask all questions that come to your mind so that you can make an informed decision. Risks associated with participating in a clinical study include: No, you don’t have to pay for the drugs or the required tests and procedures. Generally study sponsors cover costs associated with any procedures that are required for this study. Participants are encouraged to talk to staff for any additional questions regarding services provided. Xcovery will be in attendance at the ECOG-ACRIN Fall 2017 in Orlando, Florida – Oct 26th-28th. Xcovery will be in attendance at the World Lung 2017 in Yokohama, Japan – Oct 15th-18th. Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery is committed to bettering lives by providing superior therapies for cancer patients. Founded in 2006 with a passion of bringing humanity back to cancer treatment, Xcovery set out to improve existing effective treatments. Lieming Ding, M.D., serves as Chairman of the Board at Xcovery. Dr. Ding currently is also the chairman and CEO of Betta Pharmaceuticals Co., Ltd. He returned to China from US in 2002 to start Betta Pharmaceuticals Co., Ltd, a company focusing on research and development of innovative drugs. In August 2011, Betta Pharmaceutical launched icotinib (Conmana), the first targeted therapy developed in China for non-small cell lung cancer, which is a milestone for the Chinese anticancer industry. In 2012 and 2014, the WIPO and SIPO of China issued Gold award to icotinib for its two invention patents. Icotinib won the first prize of the National Science and Technology Progress Award in 2016, which is the first time that the chemical and pharmaceutical industry won the prize. In the same year, icotinib also won the China Industry Award, the top accolade of industry sector. To date, icotinib has a total sales revenue of over 3.4 billion RMB and has benefited more than 100,000 patients. Dr. Ding’s accomplishment in Chinese pharmaceutical industry has won him numerous honors, such as distinguished expert of All-China Federation of Returned Overseas Chinese, Deputy of the 12th National Peoples’ Congress, key member of Chinese National Key Special Program of Innovative Drugs, and Chairman of China Pharmaceutical Innovation and Research Development Association (PhIRDA). Chris Liang, Ph.D., is the co-founder of Xcovery. He is a leading scientist in the design of protein kinase inhibitors who has authored more than 40 scientific publications and secured more than 50 patents. Dr. Liang is co-developer of Sutent®, an FDA approved multi-kinase inhibitor for resistant gastrointestinal stromal tumors, advanced renal cell carcinoma, and advanced, progressive, well-differentiated pancreatic neuroendocrine tumors, which he developed while serving as director of medicinal chemistry at SUGEN. SUGEN and Sutent® were acquired by Pfizer. Additionally, Dr. Liang served as director of medicinal chemistry at Scripps Research Institute in Florida before starting Xcovery. Fenlai Tan, M.D., Ph.D., is the Chief Medical Officer of Xcovery. He is responsible for the clinical development of Xcovery’s improved kinase inhibitors. Dr. Tan has been involved in drug development for decades and is especially experienced in clinical study design and implementation for small molecule targeted anti-cancer drugs. Dr. Tan joined Betta Pharmaceuticals Co., Ltd as VP and CMO in 2007 where he successfully led the phase I, II, III and IV clinical trials of icotinib (an EGFR tyrosine kinase inhibitor) for the treatment of advanced NSCLC harboring EGFR mutation. In 2011, icotinib (Conmana), as the first home-grown anti-cancer targeted drug, was approved by CFDA and launched in China. A comment titled “Icotinib: kick-starting the Chinese anti-cancer drug industry” was published together with the clinical data of the icotinib phase III study (ICOGEN) on the prestigious medical journal, Lancet Oncology. Kimberly Harrow has been with Xcovery since its founding and has more than 15 years of oncology research and development experience. Ms. Harrow manages the worldwide clinical operations for all of Xcovery’s development programs, including clinical trials. Ms. Harrow holds an MBA and B.S. in biology from the University of Florida. Cristina Mallory joined Xcovery in 2016 and brought with her a solid background in Finance and Accounting; having spent over 15 years at Thermo Fisher Scientific in various finance leadership role. Ms. Mallory manages the global process within finance and accounting, including business administration, compliance and human resources. Ms. Mallory holds an MBA from the University of Florida, M.S. and B.S. in Business Administration, major in Accounting from the University of St Thomas.